Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-05-01
2004-02-03
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S273700
Reexamination Certificate
active
06686379
ABSTRACT:
SUBJECT OF THE INVENTION
The present invention relates to a novel salt form of the active compound pantoprazole. The novel salt form can be employed in the pharmaceutical industry for the preparation of medicaments.
Prior art
Pyridin-2-ylmethylsulfinyl-1H-benzimidazoles, such as are disclosed, for example, in EP-A-005129, EP-A-0166287, EP-A-0174726 and EP-A-0268956, have, on account of their H
+
/K
+
ATPase-inhibiting action, considerable importance in the therapy of diseases which are due to increased gastric acid secretion. Examples of commercially available active compounds from this group are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: omeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl 4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulfinyil]-1H-benzimidazole (INN: lansoprazole) and 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl}-1H-benzimidazole (INN: rabeprazole).
A common property of the abovementioned pyridin-2-ylmethylsulfinyl-1H-benzimidazoles is the acid sensitivity-which is in the end indispensable for their efficacy-of these active compounds, which is seen in their strong tendency to decompose in a neutral and, in particular, acidic environment, strongly colored decomposition products being formed.
In the past, there have been considerable efforts, despite the acid sensitivity of the pyridin-2-ylmethylsulfinyl-1H-benzimidazoles, to obtain stable and storable oral administration forms which contain these pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. Such stable and storable oral administration forms (e.g. tablets or capsules) are now obtainable. The preparation of these oral administration forms, however, is comparatively complicated and also certain precautions must be taken with respect to the packaging, in order that the administration forms have an adequate storage stability even under extreme storage conditions (e.g. in the tropics at high temperature and high atmospheric humidity).
The International Patent Application WO97/41114 describes a specific process for the preparation of magnesium salts of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. Inter alia, the preparation of the magnesium salt of pantoprazole is also described by way of example. According to the analysis data indicated, the salt prepared is pantoprazole magnesium in anhydrous form.
REFERENCES:
patent: 6410569 (2002-06-01), Kohl
patent: 0 166 287 (1986-01-01), None
patent: 91/19710 (1991-12-01), None
patent: 92/22284 (1992-12-01), None
patent: 95/01977 (1995-01-01), None
patent: 97/41114 (1997-11-01), None
Altana Pharma AG
Davis Zinna Northington
LandOfFree
Salt form of pantoprazole does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Salt form of pantoprazole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salt form of pantoprazole will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3312403